Results 91 to 100 of about 38,544 (277)

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients [PDF]

, 2011
Objectives To compare the frequency of previously in vitro-selected integrase mutations (T124A, T124A/S153F, S153Y, T124A/S153Y and L101I/T124A/S153Y) conferring resistance to S/GSK1349572 between HIV-1 subtype B integrase inhibitor (INI)-naive and ...
Armenia, D, Calvez, V, Ceccherini-Silberstein, F, Fabeni, L, Fourati, S, Katlama, C, Malet, I, Marcelin, A, Masquelier, B, Perno, CF, Sayon, S, Wirden, M   +11 more
core   +1 more source

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity

Retrovirology, 2017
Background HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration.
Céline Amadori, Yme Ubeles van der Velden, Damien Bonnard, Igor Orlov, Nikki van Bel, Erwann Le Rouzic, Laia Miralles, Julie Brias, Francis Chevreuil, Daniele Spehner, Sophie Chasset, Benoit Ledoussal, Luzia Mayr, François Moreau, Felipe García, José Gatell, Alessia Zamborlini, Stéphane Emiliani, Marc Ruff, Bruno P. Klaholz, Christiane Moog, Ben Berkhout, Montserrat Plana, Richard Benarous   +23 more
doaj   +1 more source

Systematic screening for age‐related comorbidities: Health care optimization among persons with HIV in an outpatient setting

HIV Medicine, EarlyView.
Abstract Background Age‐related comorbidities occur earlier and more frequently in people with HIV (PWH) than in the general population and have emerged as a key challenge in long‐term HIV care. Unfortunately, many of these conditions remain undiagnosed, and systematic screening in clinical practice remains limited.
Anna Katrine Haslund Roed, Anne‐Mette Lebech, Sabine Singh, Ole Kirk, Susanne Dam Nielsen   +4 more
wiley   +1 more source

The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase [PDF]

, 2015
Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of anti-HIV-1 agents. ALLINIs bind at the IN catalytic core domain (CCD) dimer interface occupying the principal binding pocket of its cellular cofactor LEDGF/p75.
Deng, Nanjie, Engelman, Alan, Fadel, Hind J, Feng, Lei, Fuchs, James R, Jena, Nivedita, Jurado, Kellie A, Kessl, Jacques J, Kvaratskhelia, Mamuka, Larue, Ross C, Levy, Ronald M, Patel, Pratiq A, Poeschla, Eric, Shkriabai, Nikoloz, Slaughter, Alison   +14 more
core   +1 more source

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

Retrovirology, 2008
HIV-1 integrase is the third enzymatic target of antiretroviral (ARV) therapy. However, few data have been published on the distribution of naturally occurring amino acid variation in this enzyme.
Gifford Robert J, Zioni Rafael, Kiuchi Mark, Liu Tommy F, Rhee Soo-Yon, Holmes Susan P, Shafer Robert W   +6 more
doaj   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Will drug resistance against dolutegravir in initial therapy ever occur? [PDF]

, 2015
Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir (RAL) and elvitegravir (EVG), DTG shows a limited cross ...
Mark A. Wainberg, Ying-Shan Han
core   +2 more sources

Congenital Malformations and Preeclampsia Associated with Integrase Inhibitor Use in Pregnancy [PDF]

, 2022
Christiana Smith, Angela J. Fought, Joyce F. Sung, Jennifer McKinney, Torri D. Metz, Kirk B. Fetters, Sarah Lazarus, Shannon Capraro, Emily Barr, Carrie Glenny, Jenna Buehler, Adriana Weinberg   +11 more
openalex   +1 more source

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

Journal of Sleep Research, EarlyView.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo, Benson Issarow, Salama Fadhil, Grace Ruselu, Ponsiano Fabian, Ayubu Garbindi, Robert N. Peck, Kathy Baisley, Saidi Kapiga, Ana C. Krieger   +9 more
wiley   +1 more source